Researchers developed FLAV-27, an epigenetic drug that inhibits G9a to restore gene expression in Alzheimer’s models. The treatment reduced amyloid and tau, improved cognition and synaptic function, ...

Palantir Technologies Inc. shares fell modestly Wednesday, closing at $152.77, down $2.31 or 1.49%, as investors locked in gains following a strong rally earlier in the month. The pullback came on ...

The 70th session of the intergovernmental UN Commission on the Status of Women (CSW) - UN's largest annual forum on gender equality – which began on 9th March 2026, is to conclude on 19th March 2026 ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering ...

Denali Therapeutics (NASDAQ:DNLI) founder and CEO Ryan Watts said 2026 is shaping up to be a pivotal year for the company as it approaches a potential first product approval and advances multiple ...

Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is ...

James E. Dentzer said, "we sold what was remaining to Oberland to clean it all up. We are now completely independent of the Erivedge stream," emphasizing an operational pivot from legacy assets.

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease.

STOCKHOLM, SE / ACCESS Newswire / March 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, ...

Jamie S. Myers, PhD, RN, AOCNS, FAAN, shares insights from a career of oncology nursing research, including advice for those new to the field. Welcome to Onc Nurse On Call, the new podcast ...